


03-02-05

IFW ✓  
1614



CERTIFICATE OF EXPRESS MAILING			
I hereby certify that this correspondence (plus any referenced attachments) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: IDS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below.			
Express Mail Label: <b>EL 993 686 597 US</b>			
Typed or print name	Jason A. Gonzalez		
Signature		Date	February 28, 2005

**PATENT**

**Attorney Docket No.: 39739-0029A**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**PATENT APPLICATION**

Inventor(s): Feng YING, et al.

Art Unit: 1614

Application No.: 10/718,948

Examiner: To Be Assigned

Filed: November 20, 2003

Customer No.: 25213

Title: METHOD FOR COUNTERACTING A  
PATHOLOGIC CHANGE IN THE  
β-ADRENERGIC PATHWAY

**INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge any fees due by this communication and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 39739-0029A).

Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: February 28, 2005

By: Sam L. Nguyen  
Sam L. Nguyen, Reg. No. 52,496

275 Middlefield Road  
Menlo Park, CA 94025-3506  
(650) 324-7000  
Customer No. 25213

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

PTO-1449

ATTY. DOCKET NO.:

39739-0029A

SERIAL NO.: 10/718,948

APPLICANT : YING, et al.

FILING DATE: 11/20/03

GROUP: 1614

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/40468	05/23/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	WO 00/61576	10/19/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Roberts and Sporn <u>Handbook of Experimental Pharmacology</u> (1990) 95:419-58.
	Massague <i>et al.</i> <u>Ann Rev Cell Biol</u> (1990) 6:597-646.
	Whitman, <u>Genes Dev.</u> 12:2445-62 (1998).
	Miyazono <i>et al.</i> , <u>Adv. Immunol.</u> 75:111-57 (2000).
	Attisano <i>et al.</i> , "Signal transduction by the TGF- $\beta$ superfamily" <u>Science</u> 296:1646-7 (2002).
	Bottinger and Bitzer, "TGF- $\beta$ signaling in renal disease" <u>Am. Soc. Nephrol.</u> 13:2600-2610 (2002).
	Topper, J.N., "TGF- $\beta$ in the cardiovascular system: molecular mechanisms of a context-specific growth factor" <u>Trends Cardiovasc. Med.</u> 10:132-7 (2000).
	Itoh <i>et al.</i> , <u>Signaling of transforming growth factor-<math>\beta</math> family</u> , <u>Eur. J. Biochem.</u> 267:6954-67 (2000).
	Xiao, R.P., <u>Sci STKE</u> Oct 16:2001(104):RE15.
	Port and Bristow, <u>J. Mol. Cell. Cardiol.</u> 33:887-905 (2001).
	Cross <i>et al.</i> , <u>Circ. Res.</u> 85:1077-1084 (1999).
	Mills, S.E., <u>J. Anim. Sci.</u> 80(E. Suppl. 1):E30-E35 (2002).
	Bristow, <u>Lancet</u> 352 (Suppl. 1) 8-14 (1998).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>		<b>ATTY. DOCKET NO.:</b> 39739-0029A		<b>SERIAL NO.:</b> 10/718,948			
		<b>APPLICANT :</b> YING, et al.					
		<b>FILING DATE:</b> 11/20/03		<b>GROUP:</b> 1614			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	Ligget S.B., <i>J. Clin. Invest.</i> 107:947-8 (2001).						
	Moniotte and Balligand, <i>Cardiovasc. Drug. Rev.</i> 2:19-26 (2002).						
	McGraw et al., <i>Am. J. Physiol. Lung Cell Mol. Physiol</i> 281:L895-903 (2001).						
	MsGraw et al., <i>Am. J. Physiol. Lung Cell. Mol. Physiol.</i> 279:L379-89 (2000).						
	Johnson, M., <i>Am. J. Respir. Crit. Care Med.</i> 158:S146-S153 (1998).						
	Ligget et al, Regulation of Cellular Signal Transduction Pathways by Desensitization and Amplification, 71-96, John Wiley and Sons, New York, 1994; S. E. Mills, 2002, <i>supra</i> , and Johnson, M., 1998, <i>supra</i> .						
	Bristow et al., <i>Circ. Res.</i> 59:297-309 (1986).						
	Brodde and Michel, <i>Pharmacol. Rev.</i> 51:651-690 (1999).						
	Ligget, <i>J. Clin. Invest.</i> 107:947-948 (2001).						
	Bristow, 1998, <i>supra</i> ; Bristow et al., <i>N. Engl. J. Med.</i> 307:205-211 (1982).						
	Nair et al., <i>J. Cel.. Physiol.</i> 164:232-239 (1995).						
	Lorita et al., <i>Am. J. Physiol. Heart. Circ. Physiol.</i> 283:H1887-1895 (2002).						
	Heath et al., <i>J. Physiol.</i> 512:779-791 (1998).						
	Strader et al., <i>J. Biol. Chem.</i> 264:13572-13580 (1989).						
	Iizuka et al., <i>J. mol. Cel.. Cardiol.</i> 26:435-440 (1994).						
	Rozankranz et al. ( <i>Am. J. Physiol. Heart. Circ. Physiol.</i> 283:H1253-1262 (2002).						
	Henson et al., <i>DNA Cell Biol.</i> 19:757-763 (2000).						
	Gibson UEM, Heid CA and Williams PM. <i>Genome Res.</i> 6, 995-1001, 1996.						
	Steinberg, <i>Cir Res.</i> 85:1101-1111 (1999).						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>			<b>ATTY. DOCKET NO.:</b> 39739-0029A		<b>SERIAL NO.:</b> 10/718,948							
			<b>APPLICANT :</b> YING, et al.									
			<b>FILING DATE:</b> 11/20/03		<b>GROUP:</b> 1614							
<b>U.S. PATENT DOCUMENTS</b>												
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE						
<b>FOREIGN PATENT DOCUMENTS</b>												
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION						
						<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="text-align: center;">YES</td> <td style="text-align: center;">NO</td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </table>	YES	NO	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
YES	NO											
<input type="checkbox"/>	<input type="checkbox"/>											
<input type="checkbox"/>	<input type="checkbox"/>											
						<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="text-align: center;">YES</td> <td style="text-align: center;">NO</td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </table>	YES	NO	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
YES	NO											
<input type="checkbox"/>	<input type="checkbox"/>											
<input type="checkbox"/>	<input type="checkbox"/>											
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>												
	Sabri <i>et al.</i> , <i>Cir Res.</i> 86:1047-1053 (2000).											
	Nogami <i>et al.</i> <i>Am. J. Physiol.</i> 266:L187-191 (1994).											
	Mak <i>et al.</i> , <i>Naunyn. Schmiedebergs. Arch. Pharmacol.</i> 362:520-525 (2000).											
	Poncelet <i>et al.</i> , <i>Kidney International</i> 56:1354-1365 (1999).											
	Zhao and Geverend, <i>Biochem. Biophys. Res. Commun.</i> 294:319-323 (2002).											
	Li <i>et al.</i> , <i>Circulation</i> 98:II-144-II-160 (1998).											
	Hanoune and Defer, <i>Annu. Rev. Pharmacol. Toxicol.</i> 41:145-174 (2001).											
	Nair <i>et al.</i> , <i>J. Cel. Physiol.</i> 164:232-239 (1995).											
	Ziao <i>et al.</i> , <i>Circ. Res.</i> 85:1092-1100 (1999).											
	Minano <i>et al.</i> , <i>Science</i> 264:582-586 (1994).											
	Liggett <i>et al.</i> , <i>Circulation</i> 101:1707-1714 (2000).											
	Communal <i>et al.</i> , <i>Circulation</i> 100:2210-2212 (1999).											
	Zhu <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 98:1607-1612 (2001).											
	Akhter <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 94:12100-12105 (1997).											
	Maurice <i>et al.</i> , <i>J. Clin. Invest.</i> 104:21-29 (1999).											
	Shah <i>et al.</i> , <i>Circulation</i> 101:408-414 (2000).											
	Henson <i>et al.</i> , <i>DNA Cell Biol.</i> 19:757-763 (2000).											
EXAMINER			DATE CONSIDERED									

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>			<b>ATTY. DOCKET NO.:</b> 39739-0029A		<b>SERIAL NO.:</b> 10/718,948	
			<b>APPLICANT :</b> YING, et al.			
			<b>FILING DATE:</b> 11/20/03		<b>GROUP:</b> 1614	
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<b>FOREIGN PATENT DOCUMENTS</b>						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES      NO
						<input type="checkbox"/> <input type="checkbox"/>
						<input type="checkbox"/> <input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	Gibson et al., Genome Res. 6, 995-1001, 1996.					
	Steinberg et al., Cir Res. 85:1101-1111 (1999).					
	Sabri et al., Cir Res. 86:1047-1053 (2000).					
EXAMINER			DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.